Aptevo Therapeutics (APVO)
1.87
+0.04 (2.19%)
Upcoming Events
Latest Headlines
Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial
September 3, 2026 8:06 AM - StreetInsider
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
September 3, 2026 8:06 AM - StreetInsider
Form D Aptevo Therapeutics Inc.
August 26, 2026 4:05 PM - SEC Filing
Form PRE 14A Aptevo Therapeutics Inc. For: Aug 21
August 21, 2026 4:16 PM - SEC Filing
Aptevo Therapeutics files prospectus for resale of 6.4M shares
August 21, 2026 4:13 PM - StreetInsider
Form S-1 Aptevo Therapeutics Inc.
August 21, 2026 4:11 PM - SEC Filing
Form 8-K Aptevo Therapeutics Inc. For: Aug 21
August 21, 2026 4:06 PM - SEC Filing
Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: CVI Investments, Inc.
August 14, 2026 2:42 PM - SEC Filing
Form 10-Q Aptevo Therapeutics Inc. For: Jun 30
August 14, 2026 8:16 AM - SEC Filing
Form 8-K Aptevo Therapeutics Inc. For: Aug 14
August 14, 2026 8:10 AM - SEC Filing
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
August 14, 2026 8:06 AM - StreetInsider
Form 8-K Aptevo Therapeutics Inc. For: Aug 12
August 13, 2026 4:37 PM - SEC Filing
Aptevo Therapeutics raises $4.5M through warrant exercise and PIPE
August 13, 2026 4:06 PM - StreetInsider
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
August 13, 2026 4:06 PM - StreetInsider
Aptevo raises $4.5M through warrant exercise and private placement
August 12, 2026 9:35 AM - StreetInsider
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
August 12, 2026 9:34 AM - StreetInsider
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Harsanyi Zsolt
August 10, 2026 9:39 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Lamothe Jeffrey G.
August 10, 2026 9:38 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Taylor Daphne
August 10, 2026 9:37 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Kwon SoYoung
August 10, 2026 9:36 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Grant Grady III
August 10, 2026 9:35 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Huebner Dirk
August 10, 2026 9:35 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Jul 17 Filed by: White Marvin L
August 10, 2026 9:34 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Abdun-Nabi Daniel
August 10, 2026 9:33 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Kunz Barbara Lopez
August 10, 2026 9:32 PM - SEC Filing
Form 4 Aptevo Therapeutics Inc. For: Aug 06 Filed by: Niederhuber John
August 10, 2026 9:30 PM - SEC Filing
Form DEF 14A Aptevo Therapeutics Inc. For: Jul 31
July 31, 2026 4:16 PM - SEC Filing
Form ARS Aptevo Therapeutics Inc. For: Dec 31
July 31, 2026 4:05 PM - SEC Filing
Form 8-K Aptevo Therapeutics Inc. For: Jul 27
July 27, 2026 4:05 PM - SEC Filing
Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone
July 27, 2026 8:06 AM - StreetInsider
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
July 27, 2026 8:06 AM - StreetInsider
Form S-8 Aptevo Therapeutics Inc.
July 24, 2026 4:06 PM - SEC Filing
Form 8-K Aptevo Therapeutics Inc. For: Jun 29
June 30, 2026 4:05 PM - SEC Filing
Aptevo gets $1.5M grant to advance APVO451 cancer therapy
June 30, 2026 8:06 AM - StreetInsider
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
June 30, 2026 8:05 AM - StreetInsider
Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: NIOWAVE, INC.
June 22, 2026 12:11 PM - SEC Filing
Form 3 Aptevo Therapeutics Inc. For: May 25 Filed by: NIOWAVE, INC.
June 22, 2026 11:45 AM - SEC Filing
Full Article List
